It was reported that utilizing siKras, a gene-targeted therapy, in two pancreatic cancer cell lines, PANC-1 and MiaPaCa-2, effectively inhibited tumor growth and obviously reduced the expression of the K-ras gene [20,34,35,36,37]. The gene discussed is KRAS; the disease is pancreatic neoplasm.